Disease Monitoring by the Tumour Markers Cyfra 21.1 and TPA in Patients With Non-Small Cell Lung Cancer

European Journal of Cancer - United Kingdom
doi 10.1016/0959-8049(95)00342-g
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Tumour Markers for Prediction of Survival and Monitoring of Remission in Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
1994English

Interleukin-10-Regulated Tumour Tolerance in Non-Small Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2017English

Ifosfamide in Patients With Recurrent Non Small Cell Lung Cancer

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
1986English

162P: Molecular Markers in Advanced Non Small Cell Lung Cancer Patients Receiving Gemcitabine & Cisplatin

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

The Clinical Utility of Circulating Tumour Cells in Patients With Small Cell Lung Cancer

Translational Lung Cancer Research
Oncology
2017English

Immune Markers in Non-Small Cell Lung Cancer: What Else Beyond Pd-L1 and Tumour Mutational Burden Is There?

Biomedical Journal of Scientific & Technical Research
2019English

Effects of Biological Markers on Overall Survival in Surgically Treated Patients With Non Small Cell Lung Cancer

Vojnosanitetski Pregled
MedicinePharmacology
2020English

HER2 Mutations in Chinese Patients With Non-Small Cell Lung Cancer

Oncotarget
Oncology
2016English

Decreased Levels of Serum Cytokeratin 19 Fragment CYFRA 21-1 Predict Objective Response to Chemotherapy in Patients With Non-Small Cell Lung Cancer

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy